Distribution of PD-L1, TROP2 and HER2- “lowness” in early triple-negative breast cancer: an opportunity for treatment de-escalation
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Distribution of PD-L1, TROP2 and HER2- “lowness” in early triple-negative breast cancer: an opportunity for treatment de-escalation ; day:18 ; month:10 ; year:2023 ; pages:1-7
Clinical and translational oncology ; (18.10.2023), 1-7
- Urheber
-
Bueno, Maria Jose
Mouron, Silvana
Caleiras, Eduardo
Martínez, Mario
Manso, Luis
Colomer, Ramón
Quintela-Fandino, Miguel
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12094-023-03329-9
- URN
-
urn:nbn:de:101:1-2024010809380888173904
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:36 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bueno, Maria Jose
- Mouron, Silvana
- Caleiras, Eduardo
- Martínez, Mario
- Manso, Luis
- Colomer, Ramón
- Quintela-Fandino, Miguel
- SpringerLink (Online service)
Ähnliche Objekte (12)
De-escalation of Systemic Therapy for Early-Stage, Node-Negative Her2+ and Triple-Negative Breast Cancer
HER2+ Early Breast Cancer: From Escalation via Targeted and Post-Neoadjuvant Treatment to De-Escalation
Escalation of neoadjuvant therapy in triple-negative breast cancer—balancing effectiveness and toxicities
The risk of PD-L1 expression misclassification in triple-negative breast cancer
Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer
Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil
Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
Real de-escalation or escalation in disguise?
PD-L1 and HER2 Expression in Gastroesophageal Cancer: a Matched Case Control Study
De-escalation of Systemic Therapy for Early-Stage, Node-Negative Her2+ and Triple-Negative Breast Cancer
HER2+ Early Breast Cancer: From Escalation via Targeted and Post-Neoadjuvant Treatment to De-Escalation
Escalation of neoadjuvant therapy in triple-negative breast cancer—balancing effectiveness and toxicities
The risk of PD-L1 expression misclassification in triple-negative breast cancer
Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer
Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil
Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
Real de-escalation or escalation in disguise?
PD-L1 and HER2 Expression in Gastroesophageal Cancer: a Matched Case Control Study
De-escalation of Systemic Therapy for Early-Stage, Node-Negative Her2+ and Triple-Negative Breast Cancer
HER2+ Early Breast Cancer: From Escalation via Targeted and Post-Neoadjuvant Treatment to De-Escalation
Escalation of neoadjuvant therapy in triple-negative breast cancer—balancing effectiveness and toxicities
The risk of PD-L1 expression misclassification in triple-negative breast cancer
Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer
Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil
Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
Real de-escalation or escalation in disguise?